{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:06:52Z","timestamp":1791490012629,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, in collaboration with Alexion Pharmaceuticals, Inc.\/AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40120-025-00855-2","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T08:36:09Z","timestamp":1769243769000},"page":"597-616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical and Humanistic Burden Among Adults with Neurofibromatosis Type\u00a01 and Symptomatic Plexiform Neurofibroma in the United States"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1806-1592","authenticated-orcid":false,"given":"Xiaoqin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolae","family":"Done","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Cunnington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Dettling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Pfefferkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leili","family":"Young-Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"issue":"4","key":"855_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1517\/13543784.2013.772979","volume":"22","author":"DH Gutmann","year":"2013","unstructured":"Gutmann DH, Blakeley JO, Korf BR, Packer RJ. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs. 2013;22(4):443\u201362.","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"855_CR2","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","volume":"20","author":"AM Gross","year":"2018","unstructured":"Gross AM, Singh G, Akshintala S, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro-oncol. 2018;20(12):1643\u201351.","journal-title":"Neuro-oncol"},{"key":"855_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00986-9","author":"AP Chen","year":"2025","unstructured":"Chen AP, Coyne GOS, Wolters PL, et al. Efficacy and safety of selumetinib in adults with neurofibromatosis type\u00a01 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase\u00a03 study. Lancet. 2025. https:\/\/doi.org\/10.1016\/S0140-6736(25)00986-9.","journal-title":"Lancet"},{"key":"855_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1146\/annurev-pathol-052016-100228","volume":"12","author":"CL Monroe","year":"2017","unstructured":"Monroe CL, Dahiya S, Gutmann DH. Dissecting clinical heterogeneity in neurofibromatosis type\u00a01. Annu Rev Pathol Mech Dis. 2017;12:53\u201374.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"3","key":"855_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/cancers13030463","volume":"13","author":"B Ozarslan","year":"2021","unstructured":"Ozarslan B, Russo T, Argenziano G, Santoro C, Piccolo V. Cutaneous findings in neurofibromatosis type\u00a01. Cancers (Basel). 2021;13(3):463.","journal-title":"Cancers (Basel)"},{"issue":"32","key":"855_CR6","doi-asserted-by":"publisher","first-page":"22571","DOI":"10.18632\/oncotarget.25181","volume":"9","author":"EJ Kahen","year":"2018","unstructured":"Kahen EJ, Brohl A, Yu D, et al. Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget. 2018;9(32):22571\u201385.","journal-title":"Oncotarget"},{"issue":"2","key":"855_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10072-021-05361-5","volume":"43","author":"I Iheanacho","year":"2022","unstructured":"Iheanacho I, Yoo HK, Yang X, Dodman S, Hughes R, Amin S. Epidemiological and clinical burden associated with plexiform neurofibromas in pediatric neurofibromatosis type-1 (NF-1): a systematic literature review. Neurol Sci. 2022;43(2):1281\u201393.","journal-title":"Neurol Sci"},{"issue":"11","key":"855_CR8","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","volume":"24","author":"MJ Fisher","year":"2022","unstructured":"Fisher MJ, Blakeley JO, Weiss BD, et al. Management of neurofibromatosis type\u00a01-associated plexiform neurofibromas. Neuro Oncol. 2022;24(11):1827\u201344.","journal-title":"Neuro Oncol"},{"issue":"8","key":"855_CR9","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","volume":"13","author":"AC Hirbe","year":"2014","unstructured":"Hirbe AC, Gutmann DH. Neurofibromatosis type\u00a01: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834\u201343.","journal-title":"Lancet Neurol"},{"issue":"2","key":"855_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1212\/01.wnl.0000168830.79997.13","volume":"65","author":"T Tucker","year":"2005","unstructured":"Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology. 2005;65(2):205\u201311.","journal-title":"Neurology"},{"issue":"5","key":"855_CR11","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0022-3476(97)70092-1","volume":"131","author":"MN Needle","year":"1997","unstructured":"Needle MN, Cnaan A, Dattilo J, et al. Prognostic signs in the surgical management of plexiform neurofibroma: the Children\u2019s Hospital of Philadelphia experience, 1974\u20131994. J Pediatr. 1997;131(5):678\u201382.","journal-title":"J Pediatr"},{"key":"855_CR12","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s40265-020-01331-x","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A, Keam SJ. Selumetinib: first approval. Drugs. 2020;80:931\u20137.","journal-title":"Drugs"},{"key":"855_CR13","unstructured":"US Food and Drug Administration. FDA approves selumetinib for pediatric patients 1\u00a0year of age and older with neurofibromatosis type\u00a01 with symptomatic, inoperable plexiform neurofibromas. 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selumetinib-pediatric-patients-1-year-age-and-older-neurofibromatosis-type-1. Accessed 2025 Oct 21."},{"key":"855_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03361-4","author":"AM Gross","year":"2025","unstructured":"Gross AM, O\u2019Sullivan Coyne G, Dombi E, et al. Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase\u00a02 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-024-03361-4.","journal-title":"Nat Med"},{"key":"855_CR15","unstructured":"US Food and Drug Administration. FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection 2025 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mirdametinib-adult-and-pediatric-patients-neurofibromatosis-type-1-who-have-symptomatic]. Accessed 21 Oct 2025."},{"issue":"6","key":"855_CR16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.24.01034","volume":"43","author":"CL Moertel","year":"2025","unstructured":"Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: a pivotal, phase\u00a0IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type\u00a01-associated plexiform neurofibroma. J Clin Oncol. 2025;43(6):716\u201329.","journal-title":"J Clin Oncol"},{"issue":"5","key":"855_CR17","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/ajmg.a.38680","volume":"176","author":"AB Rietman","year":"2018","unstructured":"Rietman AB, van Helden H, Both PH, et al. Worries and needs of adults and parents of adults with neurofibromatosis type\u00a01. Am J Med Genet A. 2018;176(5):1150\u201360.","journal-title":"Am J Med Genet A"},{"key":"855_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jpeds.2018.10.019","volume":"206","author":"J-S Lai","year":"2019","unstructured":"Lai J-S, Jensen SE, Charrow J, Listernick R. Patient reported outcomes measurement information system and quality of life in neurological disorders measurement system to evaluate quality of life for children and adolescents with neurofibromatosis type\u00a01 associated plexiform neurofibroma. J Pediatr. 2019;206:190\u20136.","journal-title":"J Pediatr"},{"issue":"8","key":"855_CR19","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00381-022-05513-8","volume":"38","author":"X Yang","year":"2022","unstructured":"Yang X, Yoo HK, Amin S, et al. Clinical and humanistic burden among pediatric patients with neurofibromatosis type\u00a01 and plexiform neurofibroma in the USA. Childs Nerv Syst. 2022;38(8):1513\u201322.","journal-title":"Childs Nerv Syst"},{"issue":"9","key":"855_CR20","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/ajmg.a.37123","volume":"167","author":"PL Wolters","year":"2015","unstructured":"Wolters PL, Burns KM, Martin S, et al. Pain interference in youth with neurofibromatosis type\u00a01 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A. 2015;167(9):2103\u201313.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"855_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s41687-025-00877-2","volume":"9","author":"N Al Ghriwati","year":"2025","unstructured":"Al Ghriwati N, Struemph K, Martin S, et al. Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type\u00a01 and plexiform neurofibromas: qualitative findings. J Patient-Report Outcomes. 2025;9(1):46.","journal-title":"J Patient-Report Outcomes"},{"key":"855_CR22","unstructured":"Wolters P. Personal communication, March 29, 2024."},{"issue":"12","key":"855_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1530","volume":"8","author":"A Heaney","year":"2020","unstructured":"Heaney A, Wilburn J, Rouse M, et al. The development of the PlexiQoL: a patient-reported outcome measure for adults with neurofibromatosis type\u00a01-associated plexiform neurofibromas. Mol Genet Genomic Med. 2020;8(12):e1530.","journal-title":"Mol Genet Genomic Med"},{"key":"855_CR24","unstructured":"National Institute of Health. Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET) [Available from: https:\/\/clinicaltrials.gov\/study\/NCT04924608]. Accessed 21 Oct 2025."},{"key":"855_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11060-017-2723-2","volume":"137","author":"K Nutakki","year":"2018","unstructured":"Nutakki K, Varni JW, Swigonski NL. PedsQL neurofibromatosis type\u00a01 module for children, adolescents and young adults: feasibility, reliability, and validity. J Neuro-Oncol. 2018;137:337\u201347.","journal-title":"J Neuro-Oncol"},{"key":"855_CR26","unstructured":"Varni W. Scaling and scoring for the acute and standard versions of the Pediatric Quality of Life Inventory\u2122(PedsQL). 2023."},{"issue":"11","key":"855_CR27","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","volume":"63","author":"D Cella","year":"2010","unstructured":"Cella D, Riley W, Stone A, et al. The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008. J Clin Epidemiol. 2010;63(11):1179\u201394.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"855_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11060-016-2314-7","volume":"131","author":"M Talaei-Khoei","year":"2017","unstructured":"Talaei-Khoei M, Riklin E, Merker VL, et al. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis. J Neurooncol. 2017;131(2):413\u20139.","journal-title":"J Neurooncol"},{"key":"855_CR29","unstructured":"ntro to PROMIS\u00ae 5\/16\/2024 [Available from: https:\/\/www.healthmeasures.net\/explore-measurement-systems\/promis\/intro-to-promis]. Accessed 21 Oct 2025."},{"key":"855_CR30","unstructured":"Margaret Reilly Associates Inc. WPAI General Information April 2019 [Available from: http:\/\/www.reillyassociates.net\/wpai_general.html]. Accessed 21 Oct 2025."},{"issue":"8","key":"855_CR31","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","volume":"22","author":"AS Pickard","year":"2019","unstructured":"Pickard AS, Law EH, Jiang R, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931\u201341.","journal-title":"Value Health"},{"key":"855_CR32","unstructured":"EQ-5D-5L User Guide September 2019 [Available from: https:\/\/euroqol.org\/wp-content\/uploads\/2023\/11\/EQ-5D-5LUserguide-23-07.pdf]. Accessed 21 Oct 2025."},{"issue":"8","key":"855_CR33","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1001\/archotol.131.8.712","volume":"131","author":"JB Wise","year":"2005","unstructured":"Wise JB, Cryer JE, Belasco JB, Jacobs I, Elden L. Management of head and neck plexiform neurofibromas in pediatric patients with neurofibromatosis type\u00a01. Arch Otolaryngol Head Neck Surg. 2005;131(8):712\u20138.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"9","key":"855_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138543","volume":"10","author":"SJ Bartlett","year":"2015","unstructured":"Bartlett SJ, Orbai AM, Duncan T, et al. Reliability and validity of selected PROMIS measures in people with rheumatoid arthritis. PLoS ONE. 2015;10(9):e0138543.","journal-title":"PLoS ONE"},{"issue":"3","key":"855_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.dhjo.2024.101593","volume":"17","author":"ME Gannotti","year":"2024","unstructured":"Gannotti ME, Sarmiento CA, Gross PH, et al. Adults with cerebral palsy and functional decline: a cross-sectional analysis of patient-reported outcomes from a novel North American registry. Disabil Health J. 2024;17(3):101593.","journal-title":"Disabil Health J"},{"issue":"8","key":"855_CR36","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1093\/pm\/pnw187","volume":"18","author":"EN Merriwether","year":"2017","unstructured":"Merriwether EN, Rakel BA, Zimmerman MB, et al. Reliability and construct validity of the patient-reported outcomes measurement information system (PROMIS) instruments in women with fibromyalgia. Pain Med. 2017;18(8):1485\u201395.","journal-title":"Pain Med"},{"key":"855_CR37","doi-asserted-by":"publisher","first-page":"1476472","DOI":"10.3389\/fneur.2024.1476472","volume":"15","author":"A Bos-Roubos","year":"2024","unstructured":"Bos-Roubos A, Van Leeuwen H, Wingberm\u00fchle E, et al. Cognition and behavior in adults with neurofibromatosis type\u00a01. Front Neurol. 2024;15:1476472.","journal-title":"Front Neurol"},{"key":"855_CR38","doi-asserted-by":"publisher","first-page":"1119159","DOI":"10.3389\/fendo.2023.1119159","volume":"14","author":"AG Rosenberg","year":"2024","unstructured":"Rosenberg AG, Moch\u00e8l K, H\u00e4hner LM, et al. Endocrine and non-endocrine causes of fatigue in adults with neurofibromatosis type\u00a01. Front Endocrinol. 2024;14:1119159.","journal-title":"Front Endocrinol"},{"issue":"1","key":"855_CR39","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12883-023-03429-7","volume":"23","author":"HK Yoo","year":"2023","unstructured":"Yoo HK, Porteous A, Ng A, et al. Impact of neurofibromatosis type\u00a01 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey. BMC Neurol. 2023;23(1):419.","journal-title":"BMC Neurol"},{"issue":"1","key":"855_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/17407745231209224","volume":"21","author":"PL Wolters","year":"2024","unstructured":"Wolters PL, Ghriwati NA, Baker M, et al. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: results from an anonymous online survey. Clin Trials. 2024;21(1):73\u201384.","journal-title":"Clin Trials"},{"key":"855_CR41","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11136-020-02650-y","volume":"30","author":"R Jiang","year":"2021","unstructured":"Jiang R, Janssen MB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30:803\u201316.","journal-title":"Qual Life Res"},{"key":"855_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/740279","volume":"2012","author":"P Reichardt","year":"2012","unstructured":"Reichardt P, Leahy M, Garcia Del Muro X, et al. Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: the sarcoma treatment and burden of illness in North America and Europe (SABINE) study. Sarcoma. 2012;2012:740279.","journal-title":"Sarcoma"},{"issue":"1","key":"855_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12955-022-01926-w","volume":"20","author":"E Ortega-G\u00f3mez","year":"2022","unstructured":"Ortega-G\u00f3mez E, Vicente-Galindo P, Mart\u00edn-Rodero H, Galindo-Villard\u00f3n P. Detection of response shift in health-related quality of life studies: a systematic review. Health Qual Life Outcomes. 2022;20(1):20.","journal-title":"Health Qual Life Outcomes"},{"key":"855_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1037\/10382-002","volume-title":"Adaptation to changing health: response shift in quality-of-life research","author":"TA Richards","year":"2000","unstructured":"Richards TA, Folkman S. Response shift: a coping perspective. In: Adaptation to changing health: response shift in quality-of-life research. Washington, DC: American Psychological Association; 2000. p. 25\u201336."},{"issue":"5","key":"855_CR45","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/ced.12841","volume":"41","author":"NJ Korman","year":"2016","unstructured":"Korman NJ, Zhao Y, Pike J, Roberts J. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41(5):514\u201321.","journal-title":"Clin Exp Dermatol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00855-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00855-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00855-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:08:03Z","timestamp":1772798883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00855-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["855"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00855-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xiaoqin Yang is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and owns stock in Merck & Co., Inc., Rahway, NJ, USA. Nicolae Done, Marianne Cunnington, Yipeng Gao, Jack Pfefferkorn, Leili Young-Xu, and Mei Sheng Duh are employees of Analysis Group, Inc., which received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, for the conduct of the present study. Theresa Dettling is an employee of, and own stock in, Alexion, AstraZeneca Rare Disease. Pamela L. Wolters receives support from the Intramural Research Program of the National Institutes of Health (NIH) and her contributions to this project were made as part of her official duty as an NIH federal employee, are in compliance with agency policy requirements, and are considered Works of the US Government. However, the findings and conclusions presented in this paper are those of these authors and do not necessarily reflect the views of the NIH or the US Department of Health and Human Services.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This retrospective survey study was conducted in accordance with the ethical standards of the Declaration of Helsinki. The study was approved by the Pearl IRB. Consent to participate in the study was obtained from all participants. All participants signed an informed consent form regarding the publication of the data they contributed to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}